Insight Molecular Diagnostics Inc.(IMDX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Insight Molecular Diagnostics Inc. (IMDX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMDX at 27.6/100 on a 32-signal composite quality model, placing it at rank #2,575 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Insight Molecular Diagnostics Inc. reports quarterly revenue of $239.0K, net income of $-11.3M, free cash flow of $-10.0M. Top institutional holders of IMDX by reported 13-F value include BROADWOOD CAPITAL, AWM Investment Company, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. IMDX trades on the Nasdaq exchange and files with the SEC under CIK 1642380. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Insight Molecular Diagnostics Inc. directly from SEC EDGAR.